PBLS
Parabilis Medicines, Inc.
29.65
-0.37 (-1.23%)
52w low 22.66
42.49 high
35.2% of range
Financial Analysis
| (USD) | Mar 25 | Jun 25 | Mar 26 | Jun 26 | Trend |
|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 148.00K | |
| Operating Expenses | 40.24M | 36.52M | 47.45M | 51.03M | |
| R&D | 33.91M | 30.13M | 37.75M | 39.38M | |
| SG&A | 6.34M | 6.39M | 9.70M | 11.66M | |
| Operating Income | -40.24M | -36.52M | -47.45M | -50.89M | |
| EBITDA | -37.27M | -33.80M | -44.42M | -51.66M | |
| Pretax Income | -38.33M | -34.81M | -45.32M | -52.46M | |
| Net Income | -38.33M | -34.81M | -45.32M | -52.46M | |
| EPS Diluted | -0.60 | -0.56 | -0.56 | -0.54 | |
| Diluted Shares | 80.40M | 80.40M | 80.40M | 123.52M |
Revenue CAGR
--
Net Income CAGR
--
EPS CAGR
--
FCF CAGR
--
Revenue YoY
--